Division of Congenital Heart Surgery, Texas Children's Hospital, Houston, TX, USA.
Department of Surgery, Baylor College of Medicine, Houston, TX, USA.
World J Pediatr Congenit Heart Surg. 2024 Nov;15(6):703-713. doi: 10.1177/21501351241247503. Epub 2024 May 23.
Pediatric pulmonary vein stenosis (PVS) is often progressive and treatment-refractory, requiring multiple interventions. Hybrid pulmonary vein interventions (HPVIs), involving intraoperative balloon angioplasty or stent placement, leverage surgical access and customization to optimize patency while facilitating future transcatheter procedures. We review our experience with HPVI and explore potential applications of this collaborative approach. Retrospective chart review of all HPVI cases between 2009 to 2023. Ten patients with primary (n = 5) or post-repair (n = 5) PVS underwent HPVI at median age of 12.7 months (range 6.6 months-9.5 years). Concurrent surgical PVS repair was performed in 7/10 cases. Hybrid pulmonary vein intervention was performed on 17 veins, 13 (76%) with prior surgical or transcatheter intervention(s). One patient underwent intraoperative balloon angioplasty of an existing stent. In total, 18 stents (9 bare metal [5-10 mm diameter], 9 drug eluting [3.5-5 mm diameter]) were placed in 16 veins. At first angiography (median 48 days [range 7 days-2.8 years] postoperatively), 8 of 16 (50%) HPVI-stented veins developed in-stent stenosis. Two patients died from progressive PVS early in the study, one prior to planned reintervention. Median time to first pulmonary vein reintervention was 86 days (10 days-2.8 years; 8/10 patients, 13/17 veins). At median survivor follow-up of 2.2 years (2.3 months-13.1 years), 1 of 11 surviving HPVI veins were completely occluded. Hybrid pulmonary vein intervention represents a viable adjunct to existing PVS therapies, with promising flexibility to address limitations of surgical and transcatheter modalities. Reintervention is anticipated, necessitating evaluation of long-term benefits and durability as utilization increases.
儿童肺静脉狭窄(PVS)常呈进行性且治疗抵抗,需要多次干预。杂交肺静脉介入(HPVIs)包括术中球囊血管成形术或支架置入术,利用手术入路和定制化来优化通畅性,同时为未来的经导管治疗提供便利。我们回顾了我们在 HPVIs 方面的经验,并探讨了这种联合方法的潜在应用。
回顾 2009 年至 2023 年间所有 HPVIs 病例的病历。
10 例原发性(n=5)或修复后(n=5)PVS 患者在中位年龄 12.7 个月(范围 6.6 个月-9.5 岁)时接受 HPVIs。10 例中有 7 例同时行外科 PVS 修复。17 条肺静脉行杂交肺静脉介入治疗,其中 13 条(76%)曾行外科或经导管治疗。1 例患者术中对现有支架行球囊血管成形术。共在 16 条静脉中置入 18 个支架(9 个裸金属[5-10mm 直径],9 个药物洗脱[3.5-5mm 直径])。术后首次血管造影(中位数 48 天[范围 7 天-2.8 年])时,16 条 HPVIs 支架静脉中有 8 条(50%)发生支架内狭窄。2 例患者在研究早期死于进行性 PVS,1 例在计划再次干预前死亡。首次肺静脉再次干预的中位时间为 86 天(10 天-2.8 年;10 例中有 8 例,17 条静脉中有 13 条)。在中位生存随访 2.2 年(2.3 个月-13.1 年)时,11 条生存的 HPVIs 静脉中有 1 条完全闭塞。
杂交肺静脉介入是现有 PVS 治疗的可行辅助手段,具有解决手术和经导管治疗局限性的良好灵活性。需要再次干预,随着应用的增加,需要评估长期获益和耐久性。